FORTH WORTH, TX--(Marketwired - Aug 26, 2013) - Wound Management Technologies, Inc. (OTCQB: WNDM) announces an increase in sales of CellerateRX® for the second quarter, ending June 2013 up 54% over the same period in 2012. Sales year to date have risen 111% over year to date sales in 2012. Robert Lutz Jr., chief executive officer, commented, "We attribute our growing success to increased use of CellerateRx for surgical wounds in hospitals and increased use in the woundcare marketplace." Lutz added, "We will continue to expand our sales and distribution efforts with hospitals, woundcare centers, and the longterm care and hospice market places adding new accounts based on the strong efficacy of the product."

CellerateRX, which has widely been used for treatment of podiatric wounds, specifically diabetic ulcers, is now being utilized by other medical practices. These include but are not limited to the treatment of burns, surgical wounds, and dermatological procedures. These additional procedures join the already extensive list of medical conditions CellerateRX has successfully treated. Wound Management Technologies, Inc., attributes the expansion of usage for the activated collagen wound management system, CellerateRX, as a driving force for increased financial results.

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: and